Loader
research-image

In Raffles Cancer Centre, we actively seek partnerships with research organisations who share our passion in our mission to provide the best cancer care for our patients. Clinical trials constitute an integral component of patient management in Raffles Hospital. Through these trials, our patients have access to novel therapeutic agents, which have yet made available in the market,  will give hope even after their conditions have failed to respond to standard lines of treatment.

Our specialists in Raffles Cancer Centre have abundant experience as principal investigators and co-investigators of well over 50 clinical trials in various phases (phase I, II, III), both investigator-initiated and pharmaceutical company-initiated, and as part of larger international multi-centre phase III trials.

Coordinated by the Hospital ‘s Clinical Trial Unit, these trials help expand the treatment options available to patients.

All clinical trials involving humans are subjected to approval by the Hospital’s Institutional Review Board (IRB) which ensures all clinical trials are ethically acceptable and that the rights, safety and well –being of the patients are safeguarded at all times. The IRB also monitors the conduct of the clinical trials and ensures that they are in compliance with Good Clinical Practice on an ongoing basis.

No.

Indication

Title

Investigator

Status

1

Breast Cancer

HER2+ metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting.

Dr Lynette Ngo

Recruitment completed

2

Breast Cancer

Asian postmenopausal women with ER (+), HER2 (-) advanced breast cancer

Dr Lynette Ngo

Recruitment completed

3

Lung Cancer

Stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer (EGRF positive) –First line

Dr Lynette Ngo

Recruitment completed

4

Lung Cancer

Recurrent or Stage IV PD-L1+ non–small-cell lung cancer (EGRF negative) – First line

Dr Lynette Ngo

Recruiting

5

Lung Cancer

cMET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) – Second line

Dr Lynette Ngo

Recruitment completed

6

Ovarian Cancer

Platinum-Resistant/Refractory Ovarian Cancer

Dr Lynette Ngo

Recruitment completed

7

Ovarian Cancer

Previously Untreated Epithelial Ovarian Cancer

Dr Lynette Ngo

Recruiting

8

Myelofibrosis

Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Dr Daryl Tan

Recruitment completed

9

Lymphoma

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

Dr Daryl Tan

Recruiting

10

Thrombotic Microangiopathies

Atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), or hematopoietic stem cell transplant (HSCT)-associated TMA.

Dr Daryl Tan

Recruiting

11

Colorectal Cancer

Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).

Dr Donald Poon

Recruiting

12

Chronic Lymphocytic Leukemia

Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia

Dr Daryl Tan

Recruiting

13

Gastric Cancer

Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

Dr Donald Poon

Recruiting

14

Lung Cancer

First‑line treatment of patients with advanced alk‑positive non‑small cell lung cancer

Dr Lynette Ngo

Recruiting

15

B-cell lymphoma

Transplant-eligible relapsed/refractory diffuse large B-cell lymphoma in patients not achieving a complete response at pre-transplant interim assessment

Dr Daryl Tan

Recruiting

16

Non-Hodgkin’s lymphoma (iNHL)

Relapsed indolent Non-Hodgkin’s lymphoma, after 1-3 lines of treatment

Dr Daryl Tan

Upcoming

For more information, please contact:

Raffles Hospital Clinical Trials Unit
Mon - Fri: 9.00am to 5.00pm
Tel: +65 6311 2305
Emailyang_christie@rafflesmedical.com

Your participation in this research study is purely voluntary. You may withdraw your participation at any phase during the study.

Update July 2017